My Notes

Clinical care and research for patients with cancer of prostate, bladder, kidney and testis is the primary focus of my practice.

My Articles

1. Wu S, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD, Dahut WL. (2006). Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU Int. 2007 Mar;99(3):525-8. Epub 2006 Nov 28.

2. Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 2007 May; 99(5):1047-55.

3. Raja Jaber, Whitney Dessio, and Shenhong Wu. (2007). Dramatic improvement of palmar plantar erythrodysesthesia (PPE) with oral prednisone. Annals of Oncology.

4. S Wu, William L. Dahut, James L. Gulley. (2007). The use of bisphosphonates in cancer patients. (Acta Oncologica, accepted).

5. Zhu X, Wu S, Dahut WL, Parikh CR. (2007). Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 49(2):186-93.

6. Lazarski CA, Chaves FA, Jenks SA, Wu S, Richards KA, Weaver JM, Sant AJ. (2005). The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity. 23(1):29-40.

7. Chaves FA, Hou P, Wu S, Sant AJ. (2005). Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity.SJ Immunol Methods. 300(1-2):74-92.

8. Sant AJ, Beeson C, McFarland B, Cao J, Ceman S, Bryant PW, Wu S. (1999). Individual hydrogen bonds play a critical role in MHC class II: peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange. Immunol Rev. 172:239-53.

9. De Palma, R., Wu, S., and Gorski, J. Martucci, P., Troise, C., Nocera, A. and Sacerdoti, G. (1999). Identification of a Par j I derived peptide able to elicit a cellular response DR3 restricted and modulation of the response with a monosubstituted analog of the same peptide. J Immunol 162(4):1982-7.

10. Ceman S., Wu S., Jardezky TS. and Sant AJ. (1998). Alteration of a single hydrogen bond between class II and peptide results rapid degradation of class II after Ii removal. J Exp Med 188(11):2139-49.

11. Gorski J, Yassai M, Wu S, Maslanka K. (1998). T cell immunobiology of alloimmune thrombocytopenias. Arch Immunol Ther Exp (Warsz). 46(5):269-75.